Autor segons l'article: Catassi C; Elli L; Bonaz B; Bouma G; Carroccio A; Castillejo G; Cellier C; Cristofori F; de Magistris L; Dolinsek J; Dieterich W; Francavilla R; Hadjivassiliou M; Holtmeier W; Körner U; Leffler DA; Lundin KEA; Mazzarella G; Mulder CJ; Pellegrini N; Rostami K; Sanders D; Skodje GI; Schuppan D; Ullrich R; Volta U; Williams M; Zevallos VF; Zopf Y; Fasano A
Departament: Medicina i Cirurgia
Autor/s de la URV: Castillejo De Villasante, Gemma
Paraules clau: Non-celiac gluten sensitivity Irritable bowel syndrome Gastrointestinal symptom rating scale Double-blind placebo-controlled challenge Diagnosis irritable bowel syndrome gastrointestinal symptom rating scale double-blind placebo-controlled challenge diagnosis
Resum: © 2015 by the authors; licensee MDPI, Basel, Switzerland. Non-Celiac Gluten Sensitivity (NCGS) is a syndrome characterized by intestinal and extra-intestinal symptoms related to the ingestion of gluten-containing food, in subjects that are not affected by either celiac disease or wheat allergy. Given the lack of a NCGS biomarker, there is the need for standardizing the procedure leading to the diagnosis confirmation. In this paper we report experts’ recommendations on how the diagnostic protocol should be performed for the confirmation of NCGS. A full diagnostic procedure should assess the clinical response to the gluten-free diet (GFD) and measure the effect of a gluten challenge after a period of treatment with the GFD. The clinical evaluation is performed using a self-administered instrument incorporating a modified version of the Gastrointestinal Symptom Rating Scale. The patient identifies one to three main symptoms that are quantitatively assessed using a Numerical Rating Scale with a score ranging from 1 to 10. The double-blind placebo-controlled gluten challenge (8 g/day) includes a one-week challenge followed by a one-week washout of strict GFD and by the crossover to the second one-week challenge. The vehicle should contain cooked, homogeneously distributed gluten. At least a variation of 30% of one to three main symptoms between the gluten and the placebo challenge should be detected to discriminate a positive from a negative result. The guidelines provided in this paper will help the clinician to reach a firm and positive diagnosis of NCGS and facilitate the comparisons of different studies, if adopted internationally.
Àrees temàtiques: Zootecnia / recursos pesqueiros Saúde coletiva Química Psicología Planejamento urbano e regional / demografia Nutrition and dietetics Nutrition & dietetics Nutrição Medicina veterinaria Medicina iii Medicina ii Medicina i Interdisciplinar Food science Farmacia Engenharias iv Engenharias ii Enfermagem Educação física Economia Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciências agrárias i Ciência de alimentos Biotecnología
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 20726643
Adreça de correu electrònic de l'autor: gemma.castillejo@urv.cat
Data d'alta del registre: 2024-09-07
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: Nutrients. 7 (6): 4966-4977
Referència de l'ítem segons les normes APA: Catassi C; Elli L; Bonaz B; Bouma G; Carroccio A; Castillejo G; Cellier C; Cristofori F; de Magistris L; Dolinsek J; Dieterich W; Francavilla R; Hadji (2015). Diagnosis of non-celiac gluten sensitivity (NCGS): The salerno experts’ criteria. Nutrients, 7(6), 4966-4977. DOI: 10.3390/nu7064966
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2015
Tipus de publicació: Journal Publications
Repositori URV